CN102123707A - 用于经皮介入心导管插入术的达比加群 - Google Patents
用于经皮介入心导管插入术的达比加群 Download PDFInfo
- Publication number
- CN102123707A CN102123707A CN2009801318235A CN200980131823A CN102123707A CN 102123707 A CN102123707 A CN 102123707A CN 2009801318235 A CN2009801318235 A CN 2009801318235A CN 200980131823 A CN200980131823 A CN 200980131823A CN 102123707 A CN102123707 A CN 102123707A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- maleate
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KSGXQBZTULBEEQ-UHFFFAOYSA-N CCCCCCOC(NC(c(cc1)ccc1NCc1nc2cc(C(N(CCC(OCC)=O)c3ncccc3)=O)ccc2[n]1C)=N)=O Chemical compound CCCCCCOC(NC(c(cc1)ccc1NCc1nc2cc(C(N(CCC(OCC)=O)c3ncccc3)=O)ccc2[n]1C)=N)=O KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9001808P | 2008-08-19 | 2008-08-19 | |
| US61/090,018 | 2008-08-19 | ||
| PCT/EP2009/060592 WO2010020602A1 (en) | 2008-08-19 | 2009-08-17 | Dabigatran for percutaneous interventional cardiac catheterisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102123707A true CN102123707A (zh) | 2011-07-13 |
Family
ID=41258283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801318235A Pending CN102123707A (zh) | 2008-08-19 | 2009-08-17 | 用于经皮介入心导管插入术的达比加群 |
Country Status (19)
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102391250A (zh) * | 2011-08-29 | 2012-03-28 | 石药集团欧意药业有限公司 | 一种达比加群酯化合物、制备方法及其药物组合物 |
| CN102558153A (zh) * | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | 达比加群酯的新药用盐及其制备方法 |
| CN103420985A (zh) * | 2012-05-24 | 2013-12-04 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420982A (zh) * | 2012-05-24 | 2013-12-04 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
| CN103420984A (zh) * | 2012-05-24 | 2013-12-04 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103524559A (zh) * | 2012-07-05 | 2014-01-22 | 西藏海思科药业集团股份有限公司 | 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途 |
| CN103539779A (zh) * | 2012-07-13 | 2014-01-29 | 四川海思科制药有限公司 | 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2358368A1 (en) | 2008-11-11 | 2011-08-24 | Boehringer Ingelheim International GmbH | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
| CA2791561A1 (en) * | 2010-03-01 | 2011-09-09 | Ratiopharm Gmbh | Dabigatran etexilate-containing oral pharmaceutical composition |
| SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| IN2015DN02601A (cg-RX-API-DMAC7.html) * | 2012-09-28 | 2015-09-18 | Ranbaxy Lab Ltd | |
| US9399616B2 (en) | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
| WO2014149139A2 (en) | 2013-03-15 | 2014-09-25 | Verseon, Inc. | Halogenopyrazoles as inhibitors of thrombin |
| DK2968297T3 (en) | 2013-03-15 | 2019-01-07 | Verseon Inc | MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| ES2931460T3 (es) | 2015-02-27 | 2022-12-29 | Verseon Int Corporation | Compuestos de pirazol sustituido como inhibidores de serina proteasa |
| IL280078B2 (en) | 2018-07-13 | 2024-04-01 | Verseon Int Corporation | Thrombin inhibitors, formulations, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1485094B2 (de) * | 2002-03-07 | 2020-03-25 | Boehringer Ingelheim International GmbH | Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze |
| JP2008517974A (ja) * | 2004-10-25 | 2008-05-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 |
| CA2657270A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New paediatric indications for direct thrombin inhibitors |
| JP2009543842A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管分野における直接トロンビン阻害薬のための新規適応 |
| US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
-
2009
- 2009-08-17 JP JP2011523405A patent/JP2012500245A/ja active Pending
- 2009-08-17 AU AU2009284217A patent/AU2009284217A1/en not_active Abandoned
- 2009-08-17 US US13/058,920 patent/US20110301201A1/en not_active Abandoned
- 2009-08-17 EA EA201100358A patent/EA201100358A1/ru unknown
- 2009-08-17 NZ NZ591108A patent/NZ591108A/xx not_active IP Right Cessation
- 2009-08-17 MX MX2011001612A patent/MX2011001612A/es not_active Application Discontinuation
- 2009-08-17 CN CN2009801318235A patent/CN102123707A/zh active Pending
- 2009-08-17 KR KR1020117003645A patent/KR20110044230A/ko not_active Withdrawn
- 2009-08-17 CA CA2734794A patent/CA2734794A1/en not_active Abandoned
- 2009-08-17 BR BRPI0917507A patent/BRPI0917507A2/pt not_active IP Right Cessation
- 2009-08-17 WO PCT/EP2009/060592 patent/WO2010020602A1/en not_active Ceased
- 2009-08-17 EP EP09781886A patent/EP2328580A1/en not_active Withdrawn
- 2009-08-18 TW TW098127736A patent/TW201022235A/zh unknown
- 2009-08-18 AR ARP090103168A patent/AR073077A1/es unknown
-
2010
- 2010-12-15 IL IL210005A patent/IL210005A0/en unknown
-
2011
- 2011-02-11 EC EC2011010825A patent/ECSP11010825A/es unknown
- 2011-02-15 MA MA33616A patent/MA32563B1/fr unknown
- 2011-02-17 CO CO11018905A patent/CO6290686A2/es not_active Application Discontinuation
- 2011-02-18 CL CL2011000361A patent/CL2011000361A1/es unknown
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102391250A (zh) * | 2011-08-29 | 2012-03-28 | 石药集团欧意药业有限公司 | 一种达比加群酯化合物、制备方法及其药物组合物 |
| CN102558153A (zh) * | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | 达比加群酯的新药用盐及其制备方法 |
| CN103420985A (zh) * | 2012-05-24 | 2013-12-04 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420982A (zh) * | 2012-05-24 | 2013-12-04 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
| CN103420984A (zh) * | 2012-05-24 | 2013-12-04 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420984B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420982B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
| CN103420985B (zh) * | 2012-05-24 | 2015-09-23 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103524559A (zh) * | 2012-07-05 | 2014-01-22 | 西藏海思科药业集团股份有限公司 | 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途 |
| CN103524559B (zh) * | 2012-07-05 | 2016-09-28 | 西藏海思科药业集团股份有限公司 | 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途 |
| CN103539779A (zh) * | 2012-07-13 | 2014-01-29 | 四川海思科制药有限公司 | 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途 |
| CN103539779B (zh) * | 2012-07-13 | 2016-12-21 | 四川海思科制药有限公司 | 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110044230A (ko) | 2011-04-28 |
| AU2009284217A1 (en) | 2010-02-25 |
| AR073077A1 (es) | 2010-10-13 |
| JP2012500245A (ja) | 2012-01-05 |
| MA32563B1 (fr) | 2011-08-01 |
| TW201022235A (en) | 2010-06-16 |
| IL210005A0 (en) | 2011-02-28 |
| ECSP11010825A (es) | 2011-03-31 |
| WO2010020602A1 (en) | 2010-02-25 |
| CL2011000361A1 (es) | 2011-06-17 |
| EA201100358A1 (ru) | 2011-10-31 |
| MX2011001612A (es) | 2011-03-04 |
| BRPI0917507A2 (pt) | 2015-11-17 |
| EP2328580A1 (en) | 2011-06-08 |
| NZ591108A (en) | 2012-11-30 |
| CA2734794A1 (en) | 2010-02-25 |
| US20110301201A1 (en) | 2011-12-08 |
| CO6290686A2 (es) | 2011-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201022235A (en) | New use of dabigatran | |
| CN100528157C (zh) | 3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型 | |
| RU2072840C1 (ru) | Твердая лекарственная форма пролонгированного действия для лечения сердечно-сосудистых заболеваний | |
| US20180221359A1 (en) | Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate | |
| CN101980697A (zh) | 制备口服给药的达比加群制剂的方法 | |
| US20110306640A1 (en) | Dabigatran in tumour therapy | |
| US20130109722A1 (en) | Use of dabigatran etexilate for treating patients with pulmonary hypertension | |
| US20120142703A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| JP2007518755A (ja) | モノアミン神経伝達物質再取り込み阻害剤及びn−メチル−d−アスパラギン酸(nmda)受容体アンタゴニストを含む医薬組成物 | |
| CN111150714A (zh) | 一种甲磺酸达比加群酯固体药物制剂及其制备方法 | |
| JP2003500348A (ja) | 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤 | |
| TW201124143A (en) | Emergency interventions of active charcoal with dabigatran etexilate overdosing | |
| CN101632668A (zh) | 口服药物组合物 | |
| HK1154499A (en) | Dabigatran for percutaneous interventional cardiac catheterisation | |
| JP2002518330A (ja) | 処置方法 | |
| HK1078792B (en) | Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally | |
| HK1135337A (en) | Orally administered pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1154499 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110713 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1154499 Country of ref document: HK |